Stocks to Watch:

Johnson & Johnson Earnings Beat Boosted by Hepatitis Drug

Now watching

Next video starts in : 7 Play

Johnson & Johnson Earnings Beat Boosted by Hepatitis Drug

Johnson & Johnson Earnings Beat Boosted by Hepatitis Drug
Replay video
Up next

Oil Rally Gushes On, Brent Crude Hits $50 a Barrel on Lower Supplies

Unlock your personal NFL Now stream by signing in to NFL.com

Johnson & Johnson Earnings Beat Boosted by Hepatitis Drug

by TheStreet 1:15 mins

Shares of Johnson & Johnson are in focus on Tuesday after the company posted second quarter results which were better than what Wall Street was expecting. Johnson & Johnson says sales around the world were strong. Excluding one time charges, J&J earned $1.66 a share, that's more than 10 cents better than expectations. Revenue for the quarter was $19.5 billion, slightly better than expectations and a 9% increase compared to the same period a year ago. The highlight of the quarter were sales in the U.S. which jumped almost 15%. International sales rose more than 4%. The new star product was the hepatitis C treatment Olysio. Sales for the drug reached $831 million globally in the second quarter, more than doubled its sales in the first quarter of this year. TheStreet's Julia Sun reports from New York.

View Comments (0)